Potential cellular receptors involved in hepatitis C virus entry into cells

Lipids in Health and Disease

Beat Muellhaupt¹  Daniel Favre¹ 

[1] Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Zürich, Rämistrasse 100, CH-8091 Zürich, Switzerland

关键词: statins;    lipids;    infection;    dextran sulfate;    receptor;    exosomes;    SR-B1;    CD81;    LDL;    low density lipoproteins;    HCV;    hepatitis C virus;   

Others  :  1213261
DOI  :  10.1186/1476-511X-4-9

 received in 2005-04-08, accepted in 2005-04-19,  发布年份 2005

【 摘 要 】

Hepatitis C virus (HCV) infects hepatocytes and leads to permanent, severe liver damage. Since the genomic sequence of HCV was determined, progress has been made towards understanding the functions of the HCV-encoded proteins and identifying the cellular receptor(s) responsible for adsorption and penetration of the virus particle into the target cells. Several cellular receptors for HCV have been proposed, all of which are associated with lipid and lipoprotein metabolism. This article reviews the cellular receptors for HCV and suggests a general model for HCV entry into cells, in which lipoproteins play a crucial role.

【 授权许可】

   
2005 Favre and Muellhaupt; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345(1):41-52.
• [2]Koike K, Tsutsumi T, Fujie H, Shintani Y, Kyoji M: Molecular mechanism of viral hepatocarcinogenesis. Oncology 2002, 62(Suppl 1):29-37.
• [3]Moriishi K, Matsuura Y: Mechanisms of hepatitis C virus infection. Antivir Chem Chemother 2003, 14(6):285-297.
• [4]Nishioka T, Chayama K: [Mechanism of HCV cell entry mediated by envelope and receptor proteins]. Nippon Rinsho 2004, 62 Suppl 7(Pt 1):195-198.
• [5]Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA: Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999, 73(8):6235-6244.
• [6]Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, et al.: Binding of hepatitis C virus to CD81. Science 1998, 282(5390):938-941.
• [7]Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A: The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. Embo J 2002, 21(19):5017-5025.
• [8]Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R: Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999, 57(3):223-229.
• [9]Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX: Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999, 96(22):12766-12771.
• [10]Levy S, Todd SC, Maecker HT: CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998, 16:89-109.
• [11]Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T: CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 2004, 101(19):7270-7274.
• [12]Lambot M, Fretier S, Op De Beeck A, Quatannens B, Lestavel S, Clavey V, Dubuisson J: Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment. J Biol Chem 2002, 277(23):20625-20630.
• [13]Higginbottom A, Quinn ER, Kuo CC, Flint M, Wilson LH, Bianchi E, Nicosia A, Monk PN, McKeating JA, Levy S: Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol 2000, 74(8):3642-3649.
• [14]Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003, 100(12):7271-7276.
• [15]Tan YJ, Lim SP, Ng P, Goh PY, Lim SG, Tan YH, Hong W: CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo. Virology 2003, 308(2):250-269.
• [16]Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA: CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 2004, 78(3):1448-1455.
• [17]Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, et al.: Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 2000, 74(10):4824-4830.
• [18]Meola A, Sbardellati A, Bruni Ercole B, Cerretani M, Pezzanera M, Ceccacci A, Vitelli A, Levy S, Nicosia A, Traboni C, et al.: Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 2000, 74(13):5933-5938.
• [19]Wellnitz S, Klumpp B, Barth H, Ito S, Depla E, Dubuisson J, Blum HE, Baumert TF: Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol 2002, 76(3):1181-1193.
• [20]Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S, Uematsu Y: Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 2002, 304(2):187-196.
• [21]Krieger M, Stern DM: Series introduction: multiligand receptors and human disease. J Clin Invest 2001, 108(5):645-647.
• [22]Krieger M: Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 2001, 108(6):793-797.
• [23]Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271(5248):518-520.
• [24]Calvo D, Gomez-Coronado D, Lasuncion MA, Vega MA: CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler Thromb Vasc Biol 1997, 17(11):2341-2349.
• [25]Calvo M, Enrich C: Biochemical analysis of a caveolae-enriched plasma membrane fraction from rat liver. Electrophoresis 2000, 21(16):3386-3395.
• [26]Chung NS, Wasan KM: Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 2004, 56(9):1315-1334.
• [27]Nykjaer A, Willnow TE: The low-density lipoprotein receptor gene family: a cellular Swiss army knife? Trends Cell Biol 2002, 12(6):273-280.
• [28]Steer CJ: Receptor-mediated endocytosis: mechanisms, biologic function, and molecular properties. In Hepatology: a textbook of liver disease. Volume 1. Edited by Zakim D, Boyer TD. W.B. Saunders Company; 1996::149-214.
• [29]Cooper AD, Ellsworth JL: Lipoprotein metabolism. In Hepatology: a textbook of liver disease. Volume 1. Edited by Zakim D, Boyer TD. W. B. Saunders Company; 1996::92-130.
• [30]Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT: Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000, 74(21):10055-10062.
• [31]Enjoji M, Nakamuta M, Kinukawa N, Sugimoto R, Noguchi K, Tsuruta S, Iwao M, Kotoh K, Iwamoto H, Nawata H: Beta-lipoproteins influence the serum level of hepatitis C virus. Medical Science Monitor 2000, 6(5):841-844.
• [32]Favre D, Berthillon P, Trepo C: Removal of cell-bound lipoproteins: a crucial step for the efficient infection of liver cells with hepatitis C virus in vitro. C R Acad Sci III 2001, 324(12):1141-1148.
• [33]Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A: Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992, 181(5):293-300.
• [34]Thomssen R, Bonk S, Thiele A: Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol (Berl) 1993, 182(6):329-334.
• [35]Farsad K: Exosomes: novel organelles implicated in immunomodulation and apoptosis. Yale J Biol Med 2002, 75(2):95-101.
• [36]Stahl PD, Barbieri MA: Multivesicular bodies and multivesicular endosomes: the "ins and outs" of endosomal traffic. Sci STKE 2002, 2002(141):PE32.
• [37]Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G: The biogenesis and functions of exosomes. Traffic 2002, 3(5):321-330.
• [38]Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M, Yen TS, Houghton M, Pileri P, Abrignani S: Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol 2004, 34(10):2834.
• [39]de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M: Lipid raft-associated protein sorting in exosomes. Blood 2003, 102(13):4336-4344.
• [40]Fevrier B, Raposo G: Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004, 16(4):415-421.
• [41]Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183(3):1161-1172.
• [42]Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Mobius W, Hoernschemeyer J, Slot JW, Geuze HJ, Stoorvogel W: Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 2003, 278(13):10963-10972.
• [43]Thomssen R, Bonk S: Virolytic action of lipoprotein lipase on hepatitis C virus in human sera. Med Microbiol Immunol (Berl) 2002, 191(1):17-24.
• [44]Lim SP, Soo HM, Tan YH, Brenner S, Horstmann H, MacKenzie JM, Ng ML, Lim SG, Hong W: Inducible system in human hepatoma cell lines for hepatitis C virus production. Virology 2002, 303(1):79-99.
• [45]Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Brechot C, Paranhos-Baccala G, Lotteau V: Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002, 76(14):6919-6928.
• [46]Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, Grompe M: Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000, 6(11):1229-1234.
• [47]Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000, 113(Pt 19):3365-3374.
• [48]Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ: Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998, 273(32):20121-20127.
• [49]Krieger M: Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999, 68:523-558.
• [50]Laulagnier K, Motta C, Hamdi S, Roy S, Fauvelle F, Pageaux JF, Kobayashi T, Salles JP, Perret B, Bonnerot C, et al.: Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J 2004, 380(Pt 1):161-171.
• [51]Koller-Lucae SK, Schott H, Schwendener RA: Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells. Br J Cancer 1999, 80(10):1542-1549.
• [52]McKenney JM: Lipid management: tools for getting to the goal. Am J Manag Care 2001, 7(9 Suppl):S299-306.
• [53]Stein EA: Management of hypercholesterolemia. Approach to diet and drug therapy. Am J Med 1989, 87(4A):20S-27S.
• [54]Ginsberg HN: Effects of statins on triglyceride metabolism. Am J Cardiol 1998, 81(4A):32B-35B.
• [55]Duriez P: [Mechanisms of actions of statins and fibrates]. Therapie 2003, 58(1):5-14.
• [56]Jenkins DJ, Kendall CW, Marchie A, Faulkner D, Vidgen E, Lapsley KG, Trautwein EA, Parker TL, Josse RG, Leiter LA, et al.: The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. Metabolism 2003, 52(11):1478-1483.